Sunday, 18 June 2017

The Lisbon Trilogy Slides

This week we have had a lot of interest in our paper with over 3,000 views as the final part of the Lisbon trilogy.

What's the Lisbon Trilogy

Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, 
Schmierer K. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol, Neuroimmunol Neuroinflam
4:e360; doi:10.1212/NXI.0000000000000360: 2332-7812

Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurol. 2017 Jun 12. doi: 10.1001/jamaneurol.2017.0676.

Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine. 2017;16:41-50. doi: 10.1016/j.ebiom.2017.01.042

and to counter the animal experiments that could follow

Sefia E, Pryce G, Meier UC, Giovannoni G, Baker D Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. Mult scleros is and related disorders DOI:

ProfG was asked to give a talk on the mechanisms of Action of Antibodies in MS to a group of Antibody Engineers.

ProfG could not attend so he asked me to do it, gave me his 75 slides for a 30min talk.....No chance. 

I had a few weeks to construct a story and plan my slides

So I thought, could I explain how natalizumab, daclizumab, alemtuzumab and ocrelizumab work?

Starting with daclizumab as the odd one out and having the details of of the alemtuzumab and cladribine to hand this is what the audience got.

There was one Neurologist in the Room. 


  1. Great work...Like the elephant and lion...

  2. good stuff - you're getting some attention:


Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.